论文部分内容阅读
目的:分析雷贝拉唑、阿莫西林和克拉霉素三联疗法对胃溃疡的临床疗效。方法:按照该院顺序奇偶法将我院2014年3月至2015年6月收治的60例胃溃疡患者分为观察组(n=30)及对照组(n=30)。观察组采用雷贝拉唑、阿莫西林和克拉霉素三联疗法,对照组采用阿莫西林、克拉霉素和奥美拉唑,对比两组患者不良反应发生情况及临床疗效情况。结果:观察组总有效率达86.7%,显著高于对照组70.0%(P<0.05);观察组不良反应发生率为3.3%,明显低于对照组13.3%(P<0.05)。结论:采用雷贝拉唑、阿莫西林和克拉霉素三联疗法治疗胃溃疡不仅不良反应少,而且临床疗效好,值得推广。
Objective: To analyze the clinical effect of rabeprazole, amoxicillin and clarithromycin triple therapy on gastric ulcer. Methods: Sixty patients with gastric ulcer admitted from March 2014 to June 2015 in our hospital were divided into observation group (n = 30) and control group (n = 30) according to the sequence parity method. The rabbits in the observation group were treated with rabeprazole, amoxicillin and clarithromycin. The control group was given amoxicillin, clarithromycin and omeprazole. The incidence of adverse reactions and clinical efficacy were compared between the two groups. Results: The total effective rate in the observation group was 86.7%, which was significantly higher than that in the control group (70.0%, P <0.05). The adverse reaction rate in the observation group was 3.3%, which was significantly lower than that in the control group (13.3%, P <0.05). Conclusions: The use of rabeprazole, amoxicillin and clarithromycin triple therapy in the treatment of gastric ulcer is not only less adverse reactions, and clinical efficacy is good, it is worth promoting.